InnocsAI Acquired by Liminatus Pharma | Healthcare M&A Deal

Liminatus Pharma has acquired InnocsAI, a medical devices business in California, for $0.20. Liminatus Pharma acquisitions focus on healthcare M&A, and InnocsAI provides medical device-related capabilities that can support product development and commercialization in CA. Liminatus Pharma acquires InnocsAI as a strategic acquisition to expand its medical devices acquisition footprint and strengthen its healthcare deals CA pipeline. The merger acquisition is announced, structured as a merger acquisition under a merger agreement dated May 17, 2026, with Liminatus Pharma as the strategic buyer and an under-$10M deal size.